NA
IRLA

Nordwand Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Nordwand Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$2.03K – 153
2026
Q1 		$2.03K Buy
+100
New +$20.1K ﹤0.01% 150

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nordwand Advisors's IRLA Position: Q2 2026 in Review

Nordwand Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 100 shares — an estimated $2.03K sold.

Nordwand Advisors first reported a position in IRLA in Q1 2026 and held it in 1 quarter. The position peaked at $2.03K in Q1 2026. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Nordwand Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Nordwand Advisors sold 100 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $2.03K.
  • Nordwand Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2026 and held it in 1 quarter.
  • Nordwand Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $2.03K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Nordwand Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.